About TuBerculosis Vaccine Initiative (TBVI)
TBVI (TuBerculosis Vaccine Initiative) is a non-profit foundation / research & innovation partnership that facilitates the discovery and development of new, safe and effective tuberculosis (TB) vaccines that are intended to be accessible and affordable for all people. It does so by bringing together partners globally and creating an enabling environment for TB vaccine R&D, innovation, and product development. TBVI’s mission is explicitly: “to support and facilitate discovery and development of new tuberculosis vaccines that are accessible and affordable for all.”
Collaborations with GHH-partners
Hospitals
- Amsterdam UMC: Co-authorship / joint knowledge-generation activity connected to TB vaccine clinical trial site capacity work (Amsterdam UMC is listed among affiliations in TBVI-linked work on the sub-Saharan Africa TB vaccine trial-site directory)
Universities & academic institutions
- AIGHD (Amsterdam Institute for Global Health and Development): Collaborates in TBVI-linked work on mapping TB vaccine clinical trial capacity (AIGHD appears among affiliations in TBVI-linked outputs on the sub-Saharan Africa trial-site directory).
NGO's
- Kncvtbc (KNCV Tuberculosis Foundation): Direct operational collaboration—TBVI “teamed up” / “joined forces” with KNCV to develop the directory of TB vaccine clinical trial sites in sub-Saharan Africa, commissioned by EDCTP.
- International AIDS Vaccine Initiative (IAVI): TBVI’s own news stream references joint activity around TB vaccine clinical research updates where IAVI is explicitly named as a partner/actor (e.g., announcements on trial results include IAVI among the organizations involved).
Overview of characteristics
Activities:
- Countries/regions of activity:
- Europe; TBVI coordinates European-funded R&D consortia (example: TBVAC-HORIZON is EU-funded and coordinated by TBVI).
- Africa; works on trial-site capacity mapping an enabling tools/registry for TB vaccine studies. Countries include South Africa, Tanzania, Kenya, Nigeria, Uganda, Ethiopia, Senegal, Madagascar.
Community of Practice:
- CoP1: Strengthening health systems
- CoP2: Pandemic preparedness
Themes & subthemes
Themes & sub-themes within CoP1:
- Strengthening health research system
- Strengthening clinical trial site capacity in TB-endemic countries
- Supporting research readiness of hospitals and research institutes for TB vaccine trials
- Workforce development and institutional capacity
- Building expertise among local researchers, clinicians, and trial staff through participation in international TB vaccine consortia
- Knowledge exchange between European and African research institutions
- Evidence generation to inform policy and investment
- Generating structured data on trial-site readiness and gaps, supporting funders, governments, and partners in planning TB vaccine research investments
Themes & sub-themes within CoP2:
- Vaccine research, development, and innovation
- Facilitating discovery and development of new TB vaccine candidates
- Supporting progression from early research to clinical evaluation
- Clinical trial preparedness for infectious diseases
- Ensuring trial-ready infrastructure in high-burden countries
- Maintaining a living directory of TB vaccine clinical trial sites to accelerate rapid trial deployment
- Global R&D coordination and collaboration
- Coordinating international consortia to diversify vaccine pipelines and share data
- Acting as a neutral platform connecting academia, NGO's, product developers, and funders
- Equitable access and preparedness for future outbreaks
- Explicit focus on accessible and affordable vaccines, aligning with equity principles in pandemic preparedness
Organization type:
NGO
Available resources:
- Knowledge & expertise:
- TB vaccine R&D and product-development facilitation expertise
- Product advancement support capacity. TBVI has “Product Advancement Experts” to help progress new TB vaccine candidates.
- Networks:
- Global partner convening for TB vaccine research and innovation
- Coordination of multi-stakeholder R&D portfolios.
- Tools, data, and infrastructure assets:
- Trial-site capacity intelligence and decision-support tools: TBVI (with partners) developed guidance documents, web-based tools, and a comprehensive registry/directory of trial sites in sub-Saharan Africa with TB vaccine study capacity.
- Open-access evidence products that can support partner decision-making on site selection and resource allocation
- Coordination capability:
- Consortium leadership for EU-funded R&D